The datasets analysed during the current study are available from FANTOM, GWAS Catalogue, LNCipedia, MiTranscriptome, Roadmap Epigenomics project, and Sequenced Read Archive data repositories: <http://fantom.gsc.riken.jp/5/suppl/Hon_et_al_2016/data/>, <ftp://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/OkadaY_24390342_GCST002318>, <https://lncipedia.org/download>, <http://mitranscriptome.org/download/>, <https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/core_K27ac/jointModel/final/>, and <https://www.ncbi.nlm.nih.gov/sra>, respectively.

Introduction {#sec001}
============

In keeping with other complex diseases, rheumatoid arthritis (RA) susceptibility loci are mainly non-coding, with relatively few variants having a potential impact upon the coding sequence for a protein \[[@pone.0223939.ref001],[@pone.0223939.ref002]\]. Enhancers have been identified as likely to mediate disease susceptibility at many loci. Evidence to support this generalization includes demonstrated effects of genome wide association study (GWAS) variants on enhancers at individual loci \[[@pone.0223939.ref003]\], as well as an enrichment of RA GWAS variants amongst enhancers from relevant cell types \[[@pone.0223939.ref004]\]. Alternative non-coding elements, such as long non-coding RNA (lncRNA) may also play a role in mediating the increased risk associated with non-coding variants.

lncRNA are a heterogeneous class of molecules that are defined based on a lack of protein-coding potential and a minimum transcribed length of 200 nucleotides. Whilst discrete subcategories exist, such as long intergenic non-coding RNAs, promoter associated-lncRNAs or antisense lncRNA with some discriminatory characteristics, including genomic context, overlapping chromatin marks, length and structure \[[@pone.0223939.ref005]\], it can still be difficult to discriminate a genuine lncRNA annotation from a product of spurious transcription. Many individual lncRNA have been functionally characterised, with gene regulation featuring frequently amongst the wide variety of roles described. One important subcategory was identified following observations of RNA polymerase II recruitment and transcription at enhancers \[[@pone.0223939.ref006]\]. Often described as enhancer derived RNA (eRNA), expression of these transcripts is highly correlated with enhancer activity \[[@pone.0223939.ref007]\] and increasing evidence suggests that these ncRNA may contribute towards enhancer function, although the precise mechanism is still unclear \[[@pone.0223939.ref008]\].

There is some evidence to suggest that GWAS susceptibility variants are enriched amongst lncRNA \[[@pone.0223939.ref009],[@pone.0223939.ref010]\]. However, using conventional methods of determining whether annotations overlap more than can be expected by chance it is difficult to appropriately account for confounding factors, such as chromosomal compartments or chromatin accessibility. Using the *ab initio* MiTranscriptome assembly (58,648 lncRNA), which was generated using a large collection of RNA sequencing libraries, GWAS SNPs were demonstrated to be enriched in lncRNA, compared to other SNPs tested for in GWAS analyses \[[@pone.0223939.ref009]\]. This enrichment was also observed using either GWAS SNPs or probabilistically identified causal SNPs (PICS) and lncRNA from the functional annotation of the human genome (FANTOM) cap-analysis gene expression (CAGE) associated transcriptome (CAT) assembly (27,919 lncRNA), generated using CAGE datasets in combination with existing assemblies \[[@pone.0223939.ref010]\]. Using the tissue specific nature of the FANTOM CAT annotation it was also possible to demonstrate that this enrichment was markedly higher when testing specifically for an enrichment of immune-relevant GWAS PICS in immune-expressed lncRNA transcripts.

Despite these studies, the relevance of lncRNA to the study of individual complex diseases, such as RA, remains unclear. This is especially true given the overlap in genomic locality and function between enhancers and lncRNA. We chose to investigate the overlap between lncRNA annotations, enhancer annotations and GWAS SNPs associated with RA susceptibility ([Fig 1](#pone.0223939.g001){ref-type="fig"}), with the aim of establishing to what degree the direct disruption of lncRNA by RA-associated variants may contribute to the mediation of disease risk. Central to our investigation is the use of the fgwas algorithm \[[@pone.0223939.ref011]\], which tests the ability of individual annotations to improve a probabilistic model of disease susceptibility, constructed using GWAS summary statistics. Using this method a local enrichment is estimated, that takes into consideration the non-random distribution of potentially confounding genomic features. In addition, it is possible to model multiple traits and establish the degree to which they are independently predictive.

![Visual interpretation of analysis pipeline.\
GWAS summary stats were used to inform a probabilistic model of RA susceptibility. Various features were taken from publically available data and their ability to improve this model was tested, features that improve the model can be thought of as enriched amongst RA susceptibility variants.](pone.0223939.g001){#pone.0223939.g001}

Materials and methods {#sec002}
=====================

Enrichment testing {#sec003}
------------------

Enrichment testing was performed using RA summary statistics \[[@pone.0223939.ref001]\] and fgwas v0.3.6 \[[@pone.0223939.ref011]\], with the "-cond" option called for conditional analyses. Enrichment estimates are reported as outputted by fgwas, on a log~2~ scale, such that positive values indicate an enrichment and negative values indicate a depletion of the given annotation amongst disease susceptibility variants. Chromatin state data was obtained from the Roadmap Epigenomics project \[[@pone.0223939.ref012]\], with the expanded, 18-state model used for all 98 corresponding epigenomes. These chromatin states originate from a hidden Markov model, based on H3K4me3, H3K4me1, H3K36me3, H3K27me3, H3K9me3 and H3K27ac occupancy data. In our analyses, the 18-states were combined to form four exclusive annotations as outlined in [Table 1](#pone.0223939.t001){ref-type="table"}.

10.1371/journal.pone.0223939.t001

###### Consolidation of Roadmap epigenomics 18-state chromatin states into four exclusive annotations.

![](pone.0223939.t001){#pone.0223939.t001g}

  -----------------------------------------------------------------------------------------------------------------
  TSSs                          Transcription               Enhancers                Repressed Chromatin
  ----------------------------- --------------------------- ------------------------ ------------------------------
  1\. Active TSS\               5\. Strong transcription\   7\. Genic enhancer 1\    12\. ZNF genes and repeats\
  2. Flanking TSS\              6. Weak Transcription       8. Genic enhancer 2\     13. Heterochromatin\
  3. Flanking TSS upstream\                                 9. Active enhancer 1\    16. Repressed polycomb\
  4. Flanking TSS downstream\                               10. Active enhancer 2\   17. Weak repressed polycomb\
  14. Bivalent/poised TSS                                   11. Weak enhancer\       18. Quiescent/low
                                                            15. Bivalent enhancer    

  -----------------------------------------------------------------------------------------------------------------

TSS, transcription start site; ZNF, zinc finger. The chromatin state number employed by the Roadmap Epigenomics Project is included to enable easy comparison.

The following lncRNA datasets were interrogated: Lncipedia v5.2 \[[@pone.0223939.ref013]\], miTranscriptome v2 \[[@pone.0223939.ref009]\] and FANTOM CAT (robust) \[[@pone.0223939.ref010]\].Immune-relevant enhancers were defined as genomic regions annotated as enhancers in cell-types originating from "Blood and T cell" or "HSC and B cell" anatomical locations by the Roadmap Epigenomics project \[[@pone.0223939.ref012]\]. These include a total of 17 partially overlapping primary cell populations, isolated from peripheral and umbilical cord blood; including peripheral blood mononuclear cells, B cells, Natural killer cells, haematopoietic stem cells, and various subtypes of T cells. The definition of Immune-enriched lncRNA is based on the underlying sample ontology and was wholly adopted from Hon et al. requiring: detection in at least 50% of immune-relevant samples, 5 x higher expression in immune-relevant samples than in other samples and P \< 0.05 in a one-tailed Mann--Whitney rank sum test \[[@pone.0223939.ref010]\].

Expression profiling {#sec004}
--------------------

Raw RNA-seq reads were downloaded from the Roadmap Epigenomics project for primary T-helper cells (Roadmap Epigenomics epigenome ID E043, SRA accession SRR644513 and SRR643766, originating from a 37 y old Hispanic male, and 21 y old Caucasian male, respectively) \[[@pone.0223939.ref012]\]. Reads were then filtered for quality, adapter content and polyA tails using fastp version 19.7, with default settings and polyX tail trimming enabled. Transcripts were quantified using Salmon version 13.1 \[[@pone.0223939.ref014]\] using suggested settings ("quant" mode and "--validatemappings") and using the reference index generated from the FANTOM CAT robust database \[[@pone.0223939.ref010]\]. Transcripts quantifications (reported as Transcripts per million, TPM) were then remapped to genes and summed for each gene. CAGE transcript counts per million (CPM) were taken from FANTOM CAT for T-helper cells (CL_0000084_T\_cell), as published \[[@pone.0223939.ref010]\].

Statistical difference between the distributions of immune-enriched lncRNA and mRNA abundance was established using a two-sided Z-test, with no assumption of equal variance.

Results {#sec005}
=======

Enhancer annotations from immune-relevant cell types are enriched amongst RA susceptibility variants {#sec006}
----------------------------------------------------------------------------------------------------

An enrichment of RA PICS has previously been demonstrated amongst *cis*-regulatory elements that are active in T-helper cells and lymphoblastoid cells \[[@pone.0223939.ref004]\], using data from the high density Immunochip custom SNP array. In order to establish confidence in the ability of fgwas to identify similar enrichments we sought to validate this evidence of enrichment using a more inclusive approach that incorporates the probability of association for all imputed SNPs taken from the most recent European RA GWAS meta-analysis (8 514 610, p value ranges from 1.0 to 1.94 x 10^−280^) \[[@pone.0223939.ref001]\]. In order to achieve this, chromatin state data taken from the Roadmap Epigenomics project \[[@pone.0223939.ref012]\] was incorporated in a model of RA susceptibility. Using enrichment estimates generated using the expanded 18-state model, it is possible to discern an enrichment of certain chromatin states, such as genic enhancers, active enhancers and weak enhancers in immune-relevant cell types, such as B cells, T cells and monocytes (panel A in [S1 Fig](#pone.0223939.s001){ref-type="supplementary-material"}), however the confidence intervals (CIs) for estimates are broad for many states, likely due to a reduced abundance of these annotations (panel B and C in [S1 Fig](#pone.0223939.s001){ref-type="supplementary-material"}). The size of CIs was improved by combining states to generate four more easily interpretable annotations (enhancers, transcription start sites (TSSs), transcription, and repressed chromatin; [Fig 2](#pone.0223939.g002){ref-type="fig"}). In keeping with our understanding of RA, the highest level of enrichment was observed for enhancer annotations in immune-relevant cell types, with regulatory T cells showing the highest enrichment (log~2~ enrichment 3.17, 95% CI 2.58; 3.75015). In immune-relevant cell types TSSs were also enriched, whilst repressed chromatin was depleted ([Fig 2](#pone.0223939.g002){ref-type="fig"}).

![Enrichment of chromatin state groups amongst RA susceptibility variants for 98 cell types.\
Estimates for enrichment of combined chromatin state groupings are illustrated for all 98 cell types annotated within the Roadmap Epigenomics 18-state model. Cell-types are ordered and coloured according to the clustering established by the Roadmap Epigenomics project, with immune-relevant cell types coloured green. Estimates and confidence intervals are clipped at axis limits, where applicable.](pone.0223939.g002){#pone.0223939.g002}

lncRNA annotations show negligible enrichment amongst RA susceptibility variants {#sec007}
--------------------------------------------------------------------------------

We applied fgwas to test for an enrichment of lncRNA amongst RA susceptibility variants, using lncipedia, a large lncRNA database curated from a number of sources \[[@pone.0223939.ref013]\], the MiTranscriptome assembly \[[@pone.0223939.ref009]\], and the FANTOM CAT assembly \[[@pone.0223939.ref010]\]. Using fgwas, MiTranscriptome lncRNA genes show a level of depletion amongst RA susceptibility variants comparable to repressed chromatin. MiTranscriptome lncRNA exons and both genes and exons from either FANTOM CAT or lncipedia all show negligible enrichment ([Fig 3A](#pone.0223939.g003){ref-type="fig"}).

![Enrichment of lncRNA annotations amongst RA susceptibility variants.\
Estimates for the enrichment of genic (black circle) and exonic (grey diamond) annotations from a variety of lncRNA containing databases, including 95% confidence intervals (A). Separate estimates are included for annotations identified as exhibiting enriched expression in immune-relevant cells (B).](pone.0223939.g003){#pone.0223939.g003}

lncRNA annotations with enriched expression in immune-relevant cells are subtly enriched amongst RA susceptibility variants {#sec008}
---------------------------------------------------------------------------------------------------------------------------

Uniquely, FANTOM CAT transcripts are associated with tissue specific expression data. As in the original FANTOM CAT publication, we took advantage of this additional information, to test for an enrichment of lncRNA whose expression is enriched in immune-relevant cell types amongst RA susceptibility loci. This approach demonstrated a subtle enrichment of lncRNA genes (log~2~ enrichment 0.867, 95% CI 0.0554; 1.57) and similar level of enrichment for their exons, albeit with an increased confidence interval (log~2~ enrichment 0.799, 95% CI 2.30; 1.94). FANTOM CAT mRNA annotations, whose expression is enriched in immune-relevant cell types, were included in order to provide a comparison. Genic mRNA annotations showed a similar level of enrichment as lncRNA genes, with mRNA exons exhibiting slightly higher enrichment ([Fig 3B](#pone.0223939.g003){ref-type="fig"}).

The subtle enrichment of immune-enriched lncRNA observed is not independent of immune-relevant enhancer annotations {#sec009}
-------------------------------------------------------------------------------------------------------------------

Given the strong enrichment of immune-relevant enhancers amongst RA susceptibility loci and the established overlap between lncRNA annotations and enhancers, we were interested to investigate the independence of these variables using fgwas. In this conditional analysis, a residual enrichment of immune-enriched FANTOM CAT annotations was tested after the enrichment of immune-relevant enhancers (log~2~ enrichment 3.40, 95% CI 2.54; 4.58) was accounted for ([Fig 4](#pone.0223939.g004){ref-type="fig"}). Interestingly, both lncRNA and mRNA annotations no longer show significant enrichment, indicating that once enrichment of susceptibility variants in enhancers has been accounted for no remaining enrichment of mRNA or lncRNA is apparent.

![Enrichment of immune-enriched lncRNA amongst RA susceptibility variants after conditioning on chromatin state data.\
The influence of immune-relevant enhancers (red circle) was fixed in a probabilistic model of RA susceptibility to determine whether the subtle enrichment of FANTOM CAT immune-enriched lncRNA or mRNA adds any additional predictive information and is therefore independently enriched. Genic (black circle) and exonic (grey diamond) annotations were both tested. As may be expected given the magnitude of enrichments observed, after accounting for the effect of immune-enriched FANTOM CAT annotations, the residual enrichment of immune-relevant enhancers is not dramatically reduced ([S2 Fig](#pone.0223939.s002){ref-type="supplementary-material"}).](pone.0223939.g004){#pone.0223939.g004}

Immune-enriched lncRNA are expressed at low levels in RA relevant cell types {#sec010}
----------------------------------------------------------------------------

lncRNA are generally considered to exhibit low expression levels and high tissue specificity that can make them difficult to study using conventional methods. Given their enrichment for RA susceptibility variants we were interested to establish whether this description applied to FANTOM CAT immune-enriched lncRNA in an RA relevant cell type. Using randomly primed Roadmap Epigenomics RNA-seq data from primary T-helper cells, the distribution of expression levels for FANTOM CAT immune-enriched lncRNA is significantly lower than that of FANTOM CAT immune-enriched mRNA (p = 1.04 x 10^−34^, [Fig 5A](#pone.0223939.g005){ref-type="fig"} median lncRNA transcripts per million reads (TPM); 0.257, vs 124 for mRNA). The same is true using less-conventional expression profiling methods, such as those employed by FANTOM CAT, which offer improved sensitivity for the detection of transcripts of low abundance (p = 1.01 x 10^−24^, [Fig 5B](#pone.0223939.g005){ref-type="fig"} median lncRNA counts per million reads (CPM); 1.43, vs 71.7 for mRNA). 90% of immune-enriched lncRNA have abundance lower than 85.2% of immune-enriched mRNA in Roadmap Epigenomics RNA-seq data or 75.6% of immune-enriched mRNA in FANTOM CAT CAGE data.

![Distribution of immune-enriched lncRNA and mRNA expression levels in primary T-helper cells.\
Staggered bars are used to illustrate the proportion of transcripts whose expression falls in bins of 25 million transcripts, or counts, in Roadmap Epigenomics RNA-seq data (A) and FANTOM CAT CAGE data (B), respectively.](pone.0223939.g005){#pone.0223939.g005}

Discussion {#sec011}
==========

By incorporating both cell-type specific enhancer and lncRNA annotations into a probabilistic model of RA susceptibility it is possible to demonstrate their respective levels of enrichment amongst RA susceptibility variants. Whilst previous studies have demonstrated an enrichment of lncRNA compared with randomly shuffled annotations these analyses fail to take into consideration the complex organisation of the genome and are easily confounded by alternative features. In our analysis, which incorporated lncRNA from various databases, it was only possible to demonstrate a subtle enrichment of lncRNA whose expression was previously identified as being enriched in relevant cell-types.

By conditioning a model of RA susceptibility on enhancer annotations from immune-relevant cell types it is possible to test the independence of additional features. This demonstrated that the subtle enrichment observed for immune-relevant lncRNA is entirely explained by immune-relevant enhancer annotations. Interestingly, the same is true of mRNA annotations, indicating that in both instances the primary influence of susceptibility variants is in affecting non-coding regulatory elements, with any effect on mRNA and lncRNA being secondary and/or indirect. This suggests that the majority of genetic variance in disease susceptibility is mediated through disruption of regulatory elements and not through direct disruption of transcript sequences. This observation is in keeping with those made previously, relating to the minimal overlap between the coding sequence of mRNA and RA susceptibility variants. It is also consistent with the existence of well-characterised effects of RA susceptibility variants on coding regions, such as for the HLA proteins \[[@pone.0223939.ref015]\], which convey a significant, but not exhaustive proportion of risk.

Similarly, this analysis does not rule out the relevance of lncRNA at individual loci, in fact it is worth noting that there is evidence to suggest that C5T1lncRNA may mediate risk at a RA risk locus located at chromosomal position 9q33.2, with RA associated variants falling within a C5T1lncRNA exonic region \[[@pone.0223939.ref016]\]. Our analysis, however, precludes a general effect of RA susceptibility variants on the transcribed sequence of lncRNA independent of enhancer disruption. Sequence-specific functions of lncRNA are, therefore, unlikely to mediate a significant proportion of the risk-modifying effect associated with RA susceptibility variants. Furthermore, the distribution of FANTOM-CAT immune-enriched lncRNA expression levels in primary T-helper cells highlight the difficulties associated with studying lncRNA, whose expression is typically very low and highly cell-type specific. It should however be highlighted that whilst these obstacles may complicate the functional characterisation of lncRNA, low, highly tissue specific expression on its own does not preclude a biologically significant role.

In our analysis, we have sought to highlight the difficulties associated with characterising a role for lncRNA that overlap disease susceptibility variants in mediating disease susceptibility. These difficulties have also undoubtedly contributed to limitations in the accuracy and completeness of the lncRNA annotations used, where lncRNA with low expression or with expression levels that are highly specific to a certain developmental stage, condition, or cell type are likely to be underrepresented.

Many mechanisms have been described, whereby lncRNA may impact disease susceptibility irrespective of disruptions to their DNA sequence and our findings do not limit the likelihood that these mechanisms may be important in RA susceptibility. For example, transcription of a lncRNA at a particular locus may reinforce a permissive chromatin state that is required for accurate regulation of another gene. However, where such a mechanism is found to be important in mediating the effects of a disease susceptibility variant, it is perhaps most likely that the primary impact of the disease susceptibility variants is in disrupting a regulatory element that controls the lncRNA expression. In such instances, it is inherently difficult to disentangle the functional contribution of the lncRNA and regulatory element.

The analyses performed are specific to RA, however it is assumed that similar results would be reached using GWAS data, enhancer annotations and lncRNA annotations relevant to other diseases. This would, therefore, suggest that the enrichment of lncRNA annotations amongst GWAS variants observed by others \[[@pone.0223939.ref009],[@pone.0223939.ref010]\], may result from a high degree of overlap between regulatory features such as enhancers and lncRNA and other confounding features, such as active and inactive genomic compartments. As a generalisation, when it comes to functional characterization of variants associated with complex genetic disorders, sequence-specific lncRNA functions is unlikely to represent an attractive area for study; lncRNA are not independently enriched amongst such variants and are difficult to study, due to low expression levels. Despite these results, dysregulation of lncRNA expression could still play a role in RA and similar diseases, with disease associated variants affecting regulatory elements, such as enhancers that control lncRNA expression.

fgwas represents a useful tool for studying the enrichment of different features amongst susceptibility variants, especially when used in combination with Roadmap Epigenomics data in order to identify cell-types and tissues that are relevant for disease susceptibility. Whilst using this tool we observed that the number and size of annotations that are tested have a strong influence, both on the confidence with which any enrichment is estimated, as well as on the extent of that enrichment. It is likely that this may explain some of the subtle differences observed between different lncRNA databases.

Our analyses highlight the caveats associated with inferring functional relevance for a given feature, based purely on the observation of enrichment over a genomic background, as well as the care that must be taken when attempting to interpret such enrichments. By deriving enhancer and lncRNA annotations from entirely different sources we have tried to ensure that the demonstrated dependence is not self-fulfilling, as it may have been if we defined immune-relevant lncRNA based on underlying chromatin states.

In conclusion, using fgwas and Roadmap Epigenomics chromatin state data it is possible to identify cell types and chromatin states of relevance to complex diseases, such as RA. In the case of RA this is predominantly enhancers and transcription start sites from immune-relevant cell types. It is also possible to test the association of alternative features and establish their independence from chromatin states. Here, a previously described enrichment of lncRNA amongst GWAS susceptibility loci was explored for RA. Immune-enriched lncRNA from the FANTOM-CAT database were found to be enriched amongst RA susceptibility loci, however, this enrichment was not apparent when chromatin-state data was taken into account.

Our results suggest that regulatory elements, such as enhancers, are likely to mediate the vast majority of variance in risk associated with RA and other complex diseases, with no substantial independent contribution being made by direct disruption of lncRNA sequences. Because of this, and the difficulties associated with detecting transcripts of such low abundance, sequence-specific lncRNA function does not represent the most attractive area for study with respect to RA susceptibility, except in the case of in depth characterisation of individual loci.

Supporting information {#sec012}
======================

###### Enrichment of chromatin state annotations amongst RA susceptibility variants.

Estimates for enrichment of individual states are illustrated for 98 cell types using the Roadmap Epigenomics 18-state model (a). Similar states were grouped into four groups for all immune-relevant primary cell-types (b), as individual states often gave very broad 95% confidence intervals (c). Cell-types are ordered according to the clustering established by the Roadmap Epigenomics project, with chromatin states reordered according to their subsequent grouping. Estimates and confidence intervals are clipped at axis limits, where applicable.

(TIF)

###### 

Click here for additional data file.

###### Enrichment of immune-relevant enhancers amongst RA susceptibility variants after conditioning on immune-enriched transcripts.

The influence of FANTOM CAT immune-enriched lncRNA and mRNA was fixed in a probabilistic model of RA susceptibility to confirm the independent enrichment of immune-relevant enhancer chromatin states.

(TIF)

###### 

Click here for additional data file.
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Discussion

I would like to see included some more nuanced and balanced discussion relating to the effects of lncRNAs that are not mediated through direct disruption of DNA sequence. This should include some discussion of the fact that the relatively low lncRNA expression levels may not correlate with effect size /biological relevance of specific lncRNAs. lncRNAs also show higher developmental stage specificity (as well as cell type specificity) than mRNAs, with regard to the data sources used, and the fact that these publically available resources reflect the healthy, rather than disease, state.

Minor comments on syntax

Methods. Enrichment testing. Define 'TSS' and 'HSC' at first use.

Results, line 186. Fig 3 is duplicated.

Typo fig 4A axis label.

Line 204. Complexes diseases.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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31 Jan 2020

Comments from all reviewers are gratefully received; we believe that by implementing the following recommendations the rigor and ease of understanding of our manuscript has been improved and would like to thank all reviewers for their contributions towards this.

A full list of how each of the reviewers' comments have been addressed is found below. Please note that line numbers relate to the revised manuscript with track changes.

I hope that you are satisfied with the manner in which these comments have been addressed and agree that they have improved the manuscript. Thank you once again for contributing to our manuscript in such a constructive manner.

Yours sincerely,

Dr James Ding

REVIEWER \#1:

1\. Would be possible for the authors to create a graph or a visual interpretation of the analysis pipeline implemented in the study?

A visual interpretation of the analysis pipeline has been added as an additional figure (Fig1) and referenced in the text at the end of the introduction. We hope this clarifies the approach taken.

2\. Please add more details about the RA GWAS summary statistics employ in the analysis. For instance, how many SNPs and max and min p-value of association (\~range of p-values). In order to provide the reader relevant information without having to search for the referenced paper.

We thank the reviewers for this comment as we had neglected to highlight that we restricted our analysis to the European meta-analysis as we believe this corresponds best to the ethnicity of the donors that contribute to other data-sources in our analysis. We apologise for this oversight and have sought to clarify this in the text, such that line 160-162 now reads: "...using a more inclusive approach that incorporates the probability of association for all imputed SNPs taken from the most recent European RA GWAS meta-analysis (8 514 610 SNPs, p value ranges from 1.0 to 1.94 x 10-280) \[1\]". We hope that this clarifies that no threshold was used to determine which SNPs contributed to our analysis.

3\. Could you please add more details in the methodology to the "immune-relevant enhancers definition" (page 6 lines 98 to 101)? For example, the flow cytometry antibodies (or markers) reference by the Roadmap Epigenome Project to the "Blood and T cells" or "HSC and B cell". It could be done adding them to the text or a link to Roadmap Epigenome Project.

We have included additional detail in the methods section of our paper to describe how immune-relevant enhancers were defined. This includes reference to the 6 histone marks used to contribute to the Roadmap Epigenomics Projects 18-state model (lines 109-111) and additional description of the cell types contributing to the Roadmap Epigenomics Project "Blood and T cells" or "HSC and B cell" cell type/tissue group. The relevant section (lines 125-130) now reads: "Immune-relevant enhancers were defined as genomic regions annotated as enhancers in cell-types originating from "Blood and T cell" or "HSC and B cell" anatomical locations by the Roadmap Epigenomics project \[12\]. These include a total of 17 partially overlapping primary cell populations, isolated from peripheral and umbilical cord blood; including peripheral blood mononuclear cells, B cells, Natural killer cells, haematopoietic stem cells, and various subtypes of T cells."

Additional detail can be found in Figure 2 and Supplementary Table 1 of Kundaje et al. 2015 (referenced in our manuscript as reference 12). In addition, experimental protocols from the roadmap epigenomics website detail that "Hematopoietic cells were provided as a service by the S. Heimfeld Laboratory at the Fred Hutchinson Cancer Research Center, Seattle, WA and include CD3+, CD4+, CD8+, CD14+, CD19+/CD20+, CD34+, and CD56+ cells, from both mobilized and non-mobilized donors. Cells were obtained from human leukapheresis product using standard procedures. Briefly, the lymphocyte subclasses were isolated by immunomagnetic separation using the CliniMACS affinity-based technology (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer's recommendations."

4\. A similar query as the previous one for the expression profiling section. Please add the specific cell type to which the SRA accession numbers refers to. For instance, is it from adult or fetal cells? Which flow cytometry markers?

We have included additional detail taken from the National Centre for Biotechnology Information's database, corresponding to the age, gender and ethnicity of these samples (lines 137-139). Unfortunately it has not been possible to include flow-cytometry/immunomagnetic markers as these are not clearly reported by the Roadmap Epigenomics Project. In Supplementary Table 1 of Kundaje et al. 2015 these cells are referred to as CD4+ and CD25- "Primary T helper cells from peripheral blood".

5\. Could the authors briefly explain in the methods section how to interpret the statistic (i.e. log2 enrichment) they used to "quantify" enrichment? E.g. how does it relate to the two-side Welch's test or is it the output of the fgwas? This to facilitate the understanding added to the descriptors of the enrichment measure (i.e. negligible in line 159)

This has been clarified, through the inclusion of an additional sentence in the methods section (line 104-107): "Enrichment estimates are reported as outputted by fgwas, on a log2 scale, such that positive values indicate an enrichment and negative values indicate a depletion of the given annotation amongst disease susceptibility variants."

Other points

1\. Did the authors consider to test the lncRNA/enhancer enrichment in other cellular types known to be relevant in the inflammation site of RA, such fibroblasts?

We agree that it would be of benefit to the manuscript to include additional disease relevant cell types, such as synovial fibroblasts, or fibroblast-like synoviocytes (FLS), however data sufficient to perform a comparable analysis with that performed for other cell types is not publically available. FLS show many characteristics common with fibroblasts, but they also secrete unique proteins, that are normally absent in other fibroblast lineages. Nevertheless, two primary foreskin fibroblast cell types are included in what is now Fig2, corresponding to Roadmap Epigenomics epigenome IDs E055 and E056. An enrichment of enhancer annotations from these samples was not observed.

2\. Would it be possible to narrow down the immune-related enhancer enrichment to more specific cell types? In a similar fashion as presented in figure 2b.

This has effectively been performed in what is now Fig2, which shows the extent to which enhancers annotated in all Roadmap Epigenomics epigenomes are enriched amongst RA susceptibility variants. Whilst there is some variability in the extent of this enrichment, and we report the cell type which gives the highest enrichment estimate (regulatory T cells, line 174), confidence intervals overlap to the extent that no firm comparisons can be drawn.

3\. Unfortunately, the figure 1 was not readable, possibly due to a combination of the original format and the journal submission system. Therefore, my comments are based on the rest of the content of the manuscript.

This is regrettable, especially since it appears to have relevance to the two previous points. We apologise for any contribution we have made to this and would encourage this reviewer to review this figure on bioRxiv, should it remain unreadable upon submission of our revised manuscript (<https://doi.org/10.1101/804880>).

REVIEWER \#2:

1\. Materials and Methods: For clarity and ease of reading, it would be better to summarise the data on the Roadmap Epigenomics 18-state model in a table.

This information has been transferred to a table, which we agree aids the clarity and ease of reading.

2\. Results: Lines 205-212. The assumption of normality for the two-sided Welch's t-test to test "Statistical difference between the distributions of immune-enriched lncRNA and mRNA abundance" is clearly not valid (Fig 4). The authors should either use a more appropriate alternative test, or comment on this.

Thank you for this comment, we had struggled to calculate the statistical significance of the difference between the distributions shown in what is now Fig 5, but have now found a more suitable test. Due to the large sample sizes and the central limit theorem the Z-score can be assumed to approximate a normal distribution. The significance of both comparisons is now reported as "p = 1.04 x 10-34" and "p = 1.01 x 10-24" in the results section, with the methods section (lines 147-149) reading: "Statistical difference between the distributions of immune-enriched lncRNA and mRNA abundance was established using a two-sided Z-test, without assuming equal variance."

3\. Discussion: I would like to see included some more nuanced and balanced discussion relating to the effects of lncRNAs that are not mediated through direct disruption of DNA sequence. This should include some discussion of the fact that the relatively low lncRNA expression levels may not correlate with effect size /biological relevance of specific lncRNAs. lncRNAs also show higher developmental stage specificity (as well as cell type specificity) than mRNAs, with regard to the data sources used, and the fact that these publically available resources reflect the healthy, rather than disease, state.

We have expanded our discussion (lines 289-307) in order to better cover lncRNA that are either not captured within the data sources used or function independent of their underlying DNA sequence. This includes highlighting the potential disparity between the extent to which a lncRNA may be expressed and its biological significance.

Minor comments on syntax

1\. Methods. Enrichment testing. Define 'TSS' and 'HSC' at first use.

2\. Results, line 186. Fig 3 is duplicated.

3\. Typo fig 4A axis label.

4\. Line 204. Complexes diseases.

These minor comments have all been acted upon with the underlying errors having been corrected. Thank you for your careful revision.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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